They showed that short-term lapatinib therapy caused HER2+ breast cancer cells to undergo lapatinib-induced apoptosis reliant on autophagy, but extended lapatinib treatment led to the development of protective autophagy in the formerly established lapatinib-resistant cells. Here, ERBB2 is linked to breast carcinoma.